共 50 条
- [21] BRM/SMARCA2 is a critical synthetic lethal target in BRG1-deficient cancersCANCER RESEARCH, 2014, 74 (19)Jaskelioff, MarielaHoffman, GregoryRahal, RamiXiang, KayHaas, KristySaenz-Vash, VeronicaZhai, HuiliKeen, NicholasStegmeier, FrankJagani, Zainab
- [22] Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemiaCANCER RESEARCH, 2022, 82 (12)Abbineni, ChandrasekharKhare, LeenaKuila, BilashKhaji, Abdul RawoofMahadeo, Dhaytadak BhagwanDukare, Sandeep VitthalKumar, Bhagya M. S.Gore, Suraj T.Ahuja, Vijay KamalDhudashiya, Amit A.Raghavendra, N. R.Gowda, NageshCharamanna, K. B.Aithal, Kiran B.Samiulla, D. S.Mukherjee, SubhenduAntony, ThomasGiri, SanjeevChelur, ShekarNellore, KavithaDaginakatte, GirishRamachandra, MuraliSamajdar, Susanta
- [23] Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor modelsCANCER RESEARCH, 2020, 80 (16)Berlin, MichaelCantley, JenniferWang, JingBookbinder, MarkCadelina, GregoryChan, EmilyChen, HuifenChen, XinDavenport, KimFernando, TharuGordon, DebbieHamman, BrianHaskell, RoyIshchenko, AlexeyKirkpatrick, Donald S.Maher, JonathanMerchant, MarkMoffat, JohnMorgan, AliciaNguyen, AnPizzano, JenniferQuinn, ConnorRose, Christopher M.Rousseau, EmmaSethuraman, VijayStaben, LeannaWilson, CatherineYe, XiaofenBroccatelli, FabioYauch, RobertDragovich, Peter S.
- [24] Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4-deficient solid tumorCANCER RESEARCH, 2023, 83 (07)Ito, KoichiShvartsbart, ArtemRager, JosephAgarwal, AnjanaHulse, MichaelVykuntam, KomaliWang, MinKurian, JustinCowart, MilesCote, JoySivakumar, MonishaCarter, JackBurtell, JessicaGrego, AlexMoore, AndrewBhagwat, NehaRuepp, StefanEmme, TomLu, LiangPitis, PhilipBasch, CoreyBersch, KlareMei, SongLeal, RaulRose, JohnRoth, DanielleCao, GanfengVaddi, KrisGeeganage, SandyRuggeri, BruceCombs, AndrewScherle, Peggy
- [25] Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitorsPATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)Fang, RuPan, RuiWang, XiaotongLiang, YanWang, XuanMa, HenghuiZhou, XiaojunXia, QiuyuanRao, Qiu
- [26] Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancersBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 508 (01) : 109 - 116Rago, FlorenciaDiMare, Matthew T.Elliott, GiNellRuddy, David A.Sovath, SosathyaKerr, GrainneBhang, Hyo-eun C.Jagani, Zainab
- [27] PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor ModelsJOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1262 - 1313Berlin, MichaelCantley, JenniferBookbinder, MarkBortolon, ElizabethBroccatelli, FabioCadelina, GregChan, Emily W.Chen, HuifenChen, XinCheng, YunxingCheung, Tommy K.Davenport, KimDiNicola, DeanGordon, DebbieHamman, Brian D.Harbin, AliciaHaskell, RoyHe, MingtaoHole, Alison J.Januario, ThomasKerry, Philip S.Koenig, Stefan G.Li, LimeiMerchant, MarkPerez-Dorado, InmaculadaPizzano, JenniferQuinn, ConnorRose, Christopher M.Rousseau, EmmaSoto, LeofalStaben, Leanna R.Sun, HongmingTian, QingpingWang, JingWang, WeifengYe, Crystal S.Ye, XiaofenZhang, PenghongZhou, YuhuiYauch, RobertDragovich, Peter S.
- [28] A functional screen of the epigenome identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancersMOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Jagani, ZainabHoffman, GregoryRahal, RamiBuxton, FrankMcAllister, GregoryXiang, KayFrias, ElizabethHuber, JaninaLindeman, AliciaChen, DongshuBagdasarian, LindaRomero, RodrigoRamadan, NadirePhadke, TanushreeHaas, KristyJaskelioff, MarielaWilson, BorisMeyer, MatthewMcLaughlin, Margaret E.Roberts, Charles W. M.Myer, VicPorter, JeffKeen, NicholasMickanin, CraigStegmeier, Frank
- [29] Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancersPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (08) : 3128 - 3133Hoffman, Gregory R.Rahal, RamiBuxton, FrankXiang, KayMcAllister, GregoryFrias, ElizabethBagdasarian, LindaHuber, JaninaLindeman, AliciaChen, DongshuRomero, RodrigoRamadan, NadirePhadke, TanushreeHaas, KristyJaskelioff, MarielaWilson, Boris G.Meyer, Matthew J.Saenz-Vash, VeronicaZhai, HuiliMyer, Vic E.Porter, Jeffery A.Keen, NicholasMcLaughlin, Margaret E.Mickanin, CraigRoberts, Charles W. M.Stegmeier, FrankJagani, Zainab
- [30] Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid LeukemiaBLOOD, 2024, 144 : 2774 - 2775Fultang, NormanSchwab, Ashley M.Johnson, IanGrego, AlexanderFiller, EmmaBachner, CarlyKarwoski, JakeMoore, AndrewBartilomo, AshleyAgarwal, AnjanaOsinubi, Olusola PeaceIto, KoichiAminov, SarahSahu, SrabaniUerma, AmitScherle, Peggy A.Bhagwat, NehaHeiser, Diane